tickerreport.com
Positivewww.tickerreport.com ·
cognition therapeutics nasdaqcgtx releases quarterly earnings results beats estimates by 0 01 eps
TAX_FNCACT_ANALYSTSTAX_DISEASE_ALZHEIMER_DISEASEGENERAL_HEALTHTAX_DISEASE_DISEASE
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedThe article reports a minor earnings beat for a small-cap biotech company with no revenue or commercial product. No concrete commercial mechanism, supply chain impact, or sector-wide signal is present. The beat is $0.01 per share on a loss, and the stock movement is negligible. No regulatory, investment, or demand-side catalyst is mentioned.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Cognition Therapeutics (NASDAQ:CGTX) reported Q1 2026 EPS of ($0.05), beating consensus estimate of ($0.06) by $0.01.
- Stock price rose $0.05 to $1.21 on the day of earnings release.
- Trading volume was 693,484 shares vs. average volume of 1,087,619.
- Market cap is $108.11 million, P/E ratio is -5.04, beta is 1.81.
- 52-week range: $0.22 low to $3.83 high.